10 research outputs found

    Acceso, democracia y comunidades virtuales : apropiación de tecnologías digitales desde el Cono Sur

    No full text
    Es tiempo de empezar a desarrollar tecnologías alternativas que se basen en otros modelos de negocios, en la resolución de otras necesidades, que se configuren con otros procesos, como la construcción colectiva de algoritmos, que sean procesos transparentes y abiertos, que tengan principios comunitarios de manejo de datos. Una tecnología construida por las comunidades y poblaciones que hasta ahora han sido etiquetadas como las grandes consumidoras y que nuestro grupo propone que tengan el derecho de diseñar, definir y proponer la tecnología que requieren y que quieren. Especialmente nos referimos a las mujeres, las poblaciones indígenas, las poblaciones migrantes, fronterizas, costeras, rurales, entre otros. Partimos del principio de que en estos momentos históricos en que vivimos en una sociedad digital, es un derecho humano fundamental que todo grupo social diseñe y construya la tecnología que necesita. Además, estamos convencidos y convencidas de que pueden/podemos hacerlo. Del Pronunciamiento conjunto del Grupo de Trabajo CLACSO Apropiación de Tecnologías Digitales e interseccionalidades y RIAT

    Rate of Detection of Advanced Neoplasms in Proximal Colon by Simulated Sigmoidoscopy vs Fecal Immunochemical Tests

    No full text

    Impact of age- and gender-specific cut-off values for the fecal immunochemical test for hemoglobin in colorectal cancer screening

    No full text

    Risk of COVID-19 after natural infection or vaccinationResearch in context

    No full text
    Summary: Background: While vaccines have established utility against COVID-19, phase 3 efficacy studies have generally not comprehensively evaluated protection provided by previous infection or hybrid immunity (previous infection plus vaccination). Individual patient data from US government-supported harmonized vaccine trials provide an unprecedented sample population to address this issue. We characterized the protective efficacy of previous SARS-CoV-2 infection and hybrid immunity against COVID-19 early in the pandemic over three-to six-month follow-up and compared with vaccine-associated protection. Methods: In this post-hoc cross-protocol analysis of the Moderna, AstraZeneca, Janssen, and Novavax COVID-19 vaccine clinical trials, we allocated participants into four groups based on previous-infection status at enrolment and treatment: no previous infection/placebo; previous infection/placebo; no previous infection/vaccine; and previous infection/vaccine. The main outcome was RT-PCR-confirmed COVID-19 >7–15 days (per original protocols) after final study injection. We calculated crude and adjusted efficacy measures. Findings: Previous infection/placebo participants had a 92% decreased risk of future COVID-19 compared to no previous infection/placebo participants (overall hazard ratio [HR] ratio: 0.08; 95% CI: 0.05–0.13). Among single-dose Janssen participants, hybrid immunity conferred greater protection than vaccine alone (HR: 0.03; 95% CI: 0.01–0.10). Too few infections were observed to draw statistical inferences comparing hybrid immunity to vaccine alone for other trials. Vaccination, previous infection, and hybrid immunity all provided near-complete protection against severe disease. Interpretation: Previous infection, any hybrid immunity, and two-dose vaccination all provided substantial protection against symptomatic and severe COVID-19 through the early Delta period. Thus, as a surrogate for natural infection, vaccination remains the safest approach to protection. Funding: National Institutes of Health
    corecore